Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An important contributor to the malignancy of brain tumors is their ability to infiltrate the brain. Extracellular matrix molecules and cell adhesion molecules on cell surfaces play key roles in cell migration. In the present study, we used reaggregates of dissociated cells from freshly excised human brain tumors to analyze the migration of cells from human brain tumors of different types and grades on many different adhesion proteins adsorbed to glass substrates. Proteins were chosen based on their presence in normal or neoplastic nervous tissue, and included the extra-cellular matrix molecules fibronectin, collagens, fibrinogen, laminin,
tenascin-C
, thrombospondin, and the neuron-glia cell adhesion molecule, Ng-CAM. Cells from astrocytomas (n = 24) migrated on a variety of substrates, in contrast to cells from primitive neuroectodermal tumors cells (n=6), which only migrated well on laminin, fibronectin, or type IV collagen but not on the other substrates. Typically, migrating cells from astrocytomas of all grades had long, slender processes, were usually bipolar, and their cell bodies did not spread well on any substrate. Although there was variability in the migration of cells from astrocytomas of the same grade, cells from high-grade astrocytomas tended to migrate more extensively (42.3 +/- 4.7 micrometers/16 h: n = 16) than cells from lower grade astrocytomas (28.9 +/- 3.9 micrometers/16 h; P = 0.07; n = 8); the most striking differences were observed for collagen substrates, on which cells from lower grade astrocytomas migrated at very low levels (7.6 +/- 2 .6 micrometers/16 h) and cells from high-grade astrocytomas at higher levels (24.4 +/- 5.2 micrometers;P = 0.01). In contrast to primary cells from glioblastomas (n = 13),
glioblastoma
cell lines (n = 10) consistently spread on various substrates and migrated at high levels (69.5 +/- 7.6 versus 46.4 +/-5.7 micrometers/16 h; P = 0.03), in particular, on collagens (108.4 +/- 20.2 versus 28.0 +/- 6.1 micrometers/16 h; P= 0.001). Specific monoclonal antibodies to alphaV and beta1 integrin monomers completely inhibited the migration of astrocytoma cells on most substrates, suggesting that alphaV and beta1 integrins play a crucial role in brain tumor infiltration. These studies also suggest that although a large number of extracellular matrix molecules may promote tumor cell migration, disrupting the function of only a few tumor cell receptors may be critical for tumor infiltration in the brain.
...
PMID:Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. 862 May 17
We analyzed the biodistribution of the 111In-labelled murine anti-
tenascin-C
MAb BC-2 after intralesional injection in 15
glioblastoma
patients. The activated ligand DTPA was conjugated via the isothiocyanato-benzyl group onto BC-2. Conjugates were labelled with 111In, displaying immunoreactivity greater than 90% and labelling efficiency of 99 +/- 1%. In contrast to i.v. injections, excellent tumor uptake was obtained by direct intralesional injection of conjugates that showed only slow systemic release. In serum, conjugates were found to be intact; in urine, only low-molecular-weight decay products were detected. In 8 patients, outflow from the site of injection into systemic circulation was low; daily activity in the serum and urine was found to be below 2% of the total injected radioactivity; most of the injected activity was retained within the tumor, resulting in effective half-lives of 58 +/- 5 hr. In contrast, higher outflow up to 10% of regionally injected 111In-DTPA-BC-2 MAb into systemic circulation resulted in considerable shortening of the effective half-lives to 20 to 40 hr in 7 patients. This outflow was found to correlate with tumor size and blood/brain barrier disruption. In one patient, HPLC analysis of tumor cyst fluid 3 and 6 days after intralesional injection revealed conjugates to be intact and allowed the estimate of about 70% of the total injected 111In-DTPA-BC-2 to be confined to tumor tissue. We conclude that different outflow patterns can be observed following locoregional injection of 111In-DTPA-BC-2, leading to considerable variations in the effective half-lives of isotopes within the tumor, requiring adjustment of the radiation dose in therapeutic trials.
...
PMID:Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. 918 Jan 50
Tenascin-C
exists in several polymorphic isoforms due to alternative splicing of nine fibronectin-like type III repeats. Large
Tenascin-C
isoforms are present in almost all normal adult tissues but are upregulated in fetal, regenerating, and neoplastic tissues. Here, we report a human antibody fragment, TN11, derived from a phage library with high affinity for the spliced repeat C and demonstrate that this repeat is undetectable in normal adult tissues, barely detectable or undetectable in breast, lung and gastric carcinomas, meningioma, and low grade astrocytoma, but extremely abundant in high grade astrocytoma (grade III and
glioblastoma
), especially around vascular structures and proliferating cells. The antibody appears to have potential for development of a therapeutic agent for patients with high grade astrocytoma.
...
PMID:Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. 1032 87
Tenascin-C
(
TN-C
) is an extracellular matrix protein that is overexpressed during tissue remodeling processes, including tumor growth. To identify an aptamer for testing as a tumor-selective ligand, SELEX (systematic evolution of ligands by exponential enrichment) procedures were performed using both
TN-C
and
TN-C
-expressing U251
glioblastoma
cells. The different selection techniques yielded
TN-C
aptamers that are related in sequence. In addition, a crossover procedure that switched from tumor cell to purified protein selections was effective in isolating two high-affinity
TN-C
aptamers. When targeting tumor cells in vitro, the observed propensity of naive oligonucleotide pools to evolve
TN-C
aptamers may be due to the abundance of this protein. In vivo,
TN-C
abundance may also be well suited for aptamer accumulation in the tumor milieu. A size-minimized and nuclease-stabilized aptamer, TTA1, binds to the fibrinogen-like domain of
TN-C
with an equilibrium dissociation constant (K(d)) of 5 x 10(-9) m. At 13 kDa, this aptamer is intermediate in size between peptides and single chain antibody fragments, both of which are superior to antibodies for tumor targeting because of their smaller size. TTA1 defines a new class of ligands that are intended for targeted delivery of radioisotopes or chemical agents to diseased tissues.
...
PMID:Tenascin-C aptamers are generated using tumor cells and purified protein. 1159 Jan 40
Astrocytic tumors are the most common and the most malignant primary tumors of the central nervous system. We had previously observed that gastrin could significantly modulate both cell proliferation and migration of astrocytoma cells. We have investigated in the present study which genes could be targeted by gastrin in tumor astrocyte migration. Using a subtractive hybridization PCR technique we have cloned genes differentially over-expressed in human astrocytoma U373 cells treated or not with gastrin. We found about 70 genes over-expressed by gastrin. Among the genes overexpressed by gastrin, we paid particular attention to
tenascin-C
, S100A6 and MLCK genes because their direct involvement in cell migration features. Their gastrin-induced overexpression was quantitatively determined by competitive RT-PCR technique. We also showed by means of a reporter gene system that S100A6 and
tenascin-C
respective promoters were upregulated after gastrin treatment. These data show that gastrin-mediated effects in
glioblastoma
cells occur through activation of a number of genes involved in cell migration and suggest that gastrin could be a target in new therapeutic strategies against malignant gliomas.
...
PMID:Gastrin induces over-expression of genes involved in human U373 glioblastoma cell migration. 1170 26
Tenascin-C
is an adhesion-modulatory extracellular matrix molecule that is highly expressed in tumors. To investigate the effect of
tenascin-C
on tumor cells, we analyzed its antiadhesive nature and effect on tumor cell proliferation in a fibronectin context.
Glioblastoma
and breast carcinoma cell adhesion was compromised by a mixed fibronectin/
tenascin-C
substratum, which concomitantly caused increased tumor-cell proliferation. We identified the antiadhesive mechanism as a specific interference of
tenascin-C
with cell binding to the HepII/syndecan-4 site in fibronectin through direct binding of
tenascin-C
to the 13th fibronectin type III repeat (FNIII13). Cell adhesion and proliferation levels were restored by the addition of FNIII13. Overexpression of syndecan-4, but not syndecan-1 or -2, reverted the cell adhesion defect of
tenascin-C
. We characterized FNIII13 as the binding site for syndecan-4. Thus we describe a novel mechanism by which
tenascin-C
impairs the adhesive function of fibronectin through binding to FNIII13, thereby inhibiting the coreceptor function of syndecan-4 in fibronectin-induced integrin signaling.
...
PMID:Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. 1173 46
The extracellular matrix protein
tenascin-C
is expressed in processes like embryogenesis and wound healing and in neoplasia.
Tenascin-C
expression in gliomas has been described previously; however, the relation to clinical data remains inconsistent. Generally, analysis of
tenascin-C
function is difficult due to different alternatively spliced isoforms. Our studies focus on changes in
tenascin-C
expression in human gliomas, correlating these changes with tumor progression and elucidating the functional role of the glioma cell-specific
tenascin-C
isoform pool. Eighty-six glioma tissues of different World Health Organization (WHO) grades were analyzed immunohistochemically for
tenascin-C
expression. The influence of the specific
tenascin-C
isoforms produced by
glioblastoma
cells on proliferation and migration was examined in vitro using blocking antibodies recognizing all isoforms. In general,
tenascin-C
expression increased with tumor malignancy. Perivascular staining of
tenascin-C
around tumor-supplying blood vessels was observed in all
glioblastoma
tissues, whereas in WHO II and III gliomas, perivascular
tenascin-C
staining appeared less frequently. The appearance of perivascular
tenascin-C
correlated significantly with a shorter disease-free time. Analysis of proliferation and migration in the presence of blocking antibodies revealed an inhibition of proliferation by around 30% in all 3
glioblastoma
cell cultures, as well as a decrease in migration of 30.6-46.7%. Thus we conclude that the endogenous pool of
tenascin-C
isoforms in gliomas supports both tumor cell proliferation and tumor cell migration. In addition, our data on the perivascular staining of
tenascin-C
in WHO II and III gliomas and its correlation with a shorter disease-free time suggest that
tenascin-C
may be a new and potent prognostic marker for an earlier tumor recurrence.
...
PMID:Clinical impact and functional aspects of tenascin-C expression during glioma progression. 1192 May 87
We searched by a cDNA subtraction screen for differentially expressed transcripts in MCF-7 mammary carcinoma cells grown on
tenascin-C
versus fibronectin. On
tenascin-C
, cells had irregular shapes with many processes, whereas on fibronectin they were flat with a cobble stone-like appearance. We found elevated levels of 14-3-3 tau transcripts and protein in cells grown on
tenascin-C
. To investigate the consequences of an increased level of this phospho-serine/threonine-binding adaptor protein, we transfected MCF-7 cells with a construct encoding full-length 14-3-3 tau protein and selected clones with the highest expression levels. The morphology of these cells on
tenascin-C
was flat, resembling that of cells on fibronectin. This was reflected by a similar pattern of F-actin staining on either substratum. Furthermore, the growth rate on
tenascin-C
was increased compared with the parental cells. After transient transfection of HT1080 fibrosarcoma and T98G
glioblastoma
cells with 14-3-3 tau, only the 14-3-3 tau-expressing cells were able to adhere and survive on
tenascin-C
, whereas all cells adhered well on fibronectin. Therefore, we postulate that
tenascin-C
promotes the growth of tumor cells by causing an increase in the expression of 14-3-3 tau, which in turn has a positive effect on tumor cell adhesion and growth.
...
PMID:Tenascin-C signaling through induction of 14-3-3 tau. 1252 48
The targeting of molecular repertoires to complex systems rather than biochemically pure entities is an accessible approach that can identify proteins of biological interest. We have probed antigens presented by a monolayer of tumor cells for their ability to interact with a pool of aptamers. A
glioblastoma
-derived cell line, U251, was used as the target for systematic evolution of ligands by exponential enrichment by using a single-stranded DNA library. We isolated specifically interacting oligonucleotides, and biochemical strategies were used to identify the protein target for one of the aptamers. Here we characterize the interaction of the DNA aptamer, GBI-10, with
tenascin-C
, an extracellular protein found in the tumor matrix.
Tenascin-C
is believed to be involved in both embryogenesis and oncogenesis pathways. Systematic evolution of ligands by exponential enrichment appears to be a successful strategy for the a priori identification of targets of biological interest within complex systems.
...
PMID:A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. 1467 25
Tenascin-C
is an adhesion-modulating extracellular matrix molecule that is highly expressed in tumor stroma and stimulates tumor cell proliferation. Adhesion of T98G
glioblastoma
cells to a fibronectin substratum is inhibited by
tenascin-C
. To address the mechanism of action, we performed a RNA expression analysis of T89G cells grown in the presence or absence of
tenascin-C
and found that
tenascin-C
down-regulates tropomyosin-1. Upon overexpression of tropomyosin-1, cell spreading on a fibronectin/
tenascin-C
substratum was restored, indicating that
tenascin-C
destabilizes actin stress fibers through down-regulation of tropomyosin-1.
Tenascin-C
also increased the expression of the endothelin receptor type A and stimulated the corresponding mitogen-activated protein kinase signaling pathway, which triggers extracellular signal-regulated kinase 1/2 phosphorylation and c-Fos expression.
Tenascin-C
additionally caused down-regulation of the Wnt inhibitor Dickkopf 1. In consequence, Wnt signaling was enhanced through stabilization of beta-catenin and stimulated the expression of the beta-catenin target Id2. Finally, our in vivo data derived from astrocytoma tissue arrays link increased
tenascin-C
and Id2 expression with high malignancy. Because increased endothelin and Wnt signaling, as well as reduced tropomyosin-1 expression, are closely linked to transformation and tumorigenesis, we suggest that
tenascin-C
specifically modulates these signaling pathways to enhance proliferation of glioma cells.
...
PMID:Growth promoting signaling by tenascin-C [corrected]. 1549 59
1
2
3
Next >>